Genome-Wide DNA Methylation Profiling as a Prognostic Marker in Pituitary Adenomas-A Pilot Study

Area of Science:

• Endocrinology
• Oncology
• Epigenetics

Background:

• Predicting pituitary adenoma regrowth post-surgery is challenging.
• Genome-wide DNA methylation profiling may stratify adenomas by subtype.
• Previous studies proposed genes linked to regrowth, but not epigenetic variance with clinical heterogeneity.

Purpose of the Study:

• To investigate DNA methylation profiling as a clinical prognostic marker for pituitary adenoma regrowth.
• To link epigenetic variance with regrowth potential and clinical heterogeneity in nonfunctioning pituitary adenomas.

Main Methods:

• DNA methylation analysis using Illumina's MethylationEPIC array on 42 pituitary macroadenomas.
• 3D volumetric analysis of tumor remnant volume via annual MRI for regrowth rate.
• Linear mixed effects model to assess regrowth patterns across DNA methylation clusters.

Main Results:

• Robust DNA methylation clusters identified in 42 pituitary adenoma samples.
• Five subclusters found in SF1-lineage nonfunctioning pituitary adenomas.
• Tendencies toward association between specific DNA methylation clusters and regrowth potential observed.

Conclusions:

• DNA methylation profiling may identify nonfunctioning pituitary adenomas with increased growth and recurrence potential.
• This explorative pilot study suggests potential as a clinical prognostic marker.
• Larger validation studies are needed to confirm these findings.